High impact information on D01715

• Our aim was to examine the influence of the PF-4 derived octapeptide (CT-112; TTSQVRPR) on type II collagen induced arthritis in mice, to determine if this peptide exhibited antiinflammatory properties [1].
• CONCLUSION: The topical aldose reductase inhibitor, CT-112 improves the corneal epithelial barrier function in diabetic patients [2].
• This study investigated whether diabetic-like corneal sensory deficits occur in the galactose-fed rat model of diabetic ocular complications and if such deficits could be prevented using either of two structurally different aldose reductase (AR) inhibitors, CT-112 or AL-1576 [3].
• METHODS: Forty rats were divided into 3 groups based on their diet: a control group, a galactose group and a CT-112 treated galactose group (CT-112 group) [4].
• RESULTS--Morphological variations (polymegethism and pleomorphism) of the endothelium in eight eyes from eight patients receiving CT-112 resolved within 3 months after initiation of treatment [5].

Biological context of D01715

• Reepithelialization was delayed in galactosemic rats, but the instillation of CT-112 ophthalmic solutions improved the wound healing, although no differences in efficacy was found at the concentrations used [6].

Anatomical context of D01715

• PURPOSE: To investigate whether the barrier function of the corneal epithelium is disrupted in galactosemic rats, and to assess the effects of the aldose reductase inhibitor CT-112, in the form of eyedrops, on the corneal epithelial barrier in galactosemic rats [4].
• CONCLUSIONS: These results indicate that treatment with topical CT-112 is capable of reversing abnormal morphologic characteristics of corneal epithelial cells and reduced corneal sensitivity in diabetic patients [7].
• METHOD--Wide field specular microscopy was used to evaluate the clinical efficacy of treating the diabetic corneal endothelium with topical instillation of 0.5% aldose reductase inhibitor, CT-112 [5].
• CT-112 peaked in the corneal epithelium, stroma, endothelium and aqueous humor in 30 minutes following instillation, then gradually diminished time-dependently over a period of 24 hours [8].

Associations of D01715 with other chemical compounds

• A study was made of inhibitory effects of an aldose reductase inhibitor, CT-112 (5-(3-ethoxy-4-pentyloxyphenyl)-2,4-thiazolidinedione) ophthalmic solution, on the accumulation of sugar alcohol (dulcitol) in the corneal epithelium of rats fed on a 50% galactose diet [9].

Analytical, diagnostic and therapeutic context of D01715

• A peptide sequence from platelet factor 4 (CT-112) is effective in the treatment of type II collagen induced arthritis in mice [1].
• RESULTS: CT-112 both prevented the development of arthritis in mice treated prophylactically and reduced progression of disease in animals treated therapeutically, and was active when delivered by either subcutaneous injection or oral gavage [1].
• Corneal sensitivity remained decreased in the control group, whereas that in the group treated with CT-112 significantly improved, from 5.36 to 1.37 g/mm2 (P < .0001) [7].
• The concentration of CT-112 in corneal epithelium, stroma, endothelium, lens, and aqueous humor, was sequentially determined by high-performance liquid chromatography [8].

References